Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates

1 Jan 2010

Abstract excerpt

The scatter factor/hepatocyte growth factor (HGF)-c-Met axis is involved in the malignant phenotype of various tumor types via activation of a wide range of autocrine and paracrine processes. Autocrine activation of tumor cell c-Met receptors enhances tumor cell proliferation, angiogenesis, invasion/metastasis and resistance to apoptosis and cytotoxic therapies. In addition, tumor and stroma cell-derived HGF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Computational Drug Discovery Methods
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20015007
DOI: 10.2174/1871520611009010007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesPMID 20015007Read ↗

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsSemantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR).Semantic proximity Read ↗

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.Semantic proximity Read ↗

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity <i>in vivo</i>Semantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Semantic proximity Read ↗

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

c-Met: structure, functions and potential for therapeutic inhibition.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.